(Q43426137)

23 November 2017

title

Proton pump inhibitors and risk of bone fractures (English)

1 reference

23 November 2017

2

1 reference

23 November 2017

author name string

Grigorios I Leontiadis

series ordinal

1

1 reference

23 November 2017

language of work or name

1 reference

1 December 2014

1 reference

Current treatment options in gastroenterology

23 November 2017

published in

1 reference

23 November 2017

volume

12

1 reference

23 November 2017

issue

4

1 reference

23 November 2017

page(s)

414-423

1 reference

https://scigraph.springernature.com/pub.10.1007/s11938-014-0030-y

23 November 2017

exact match

0 references

cites work

Guidelines for the diagnosis and management of gastroesophageal reflux disease

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

21 January 2018

The risks of PPI therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Long-term proton pump inhibitor therapy and risk of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Hip fracture and proton pump inhibitor therapy: balancing the evidence for benefit and harm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Hip fracture and proton pump inhibitor therapy: position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton pump inhibitors therapy and risk of hip fracture: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Meta-analysis: risk of fractures with acid-suppressing medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Use of proton pump inhibitors and risk of osteoporosis-related fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Levothyroxine dose and risk of fractures in older adults: nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Prevalence of thoracic vertebral fractures in hospitalized elderly patients with heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Hip fracture and risk of acute myocardial infarction: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Acid-suppressive medications and risk of bone loss and fracture in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Increase in vertebral fracture risk in postmenopausal women using omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Effectiveness of bisphosphonate therapy in a community setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Factors associated with the initiation of proton pump inhibitors in corticosteroid users

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Increased risk of fragility fractures among HIV infected compared to uninfected male veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton pump inhibitor use and fracture risk - effect modification by histamine H1 receptor blockade. Observational case-control study using National Prescription Data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton-pump inhibitor use and hip fractures in men: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Cardiovascular and noncardiovascular disease associations with hip fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

A comparison of frailty indexes for the prediction of falls, disability, fractures, and mortality in older men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

The interaction between proton pump inhibitors and clopidogrel and upper gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Use of proton-pump inhibitors and their associated risks among frail elderly nursing home residents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Regulation of vitamin D and calcium metabolism after gastrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Do proton pump inhibitors decrease calcium absorption?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Bone density in proton pump inhibitors users: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Incidence of Campylobacter and Salmonella infections following first prescription for PPI: a cohort study using routine data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11938-014-0030-Y

Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors

21 January 2018

1 reference

12 December 2020

Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients

1 reference

12 December 2020

Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region

1 reference

12 December 2020

Proton pump inhibitor use and the antifracture efficacy of alendronate

1 reference

12 December 2020

Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study

1 reference

12 December 2020

Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture

1 reference

12 December 2020

Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting

1 reference

12 December 2020

Risk of fractures in patients with pernicious anemia

1 reference

12 December 2020

The relationship between proton pump inhibitor adherence and fracture risk in the elderly

1 reference

12 December 2020

How much do PPIs contribute to C. difficile infections?

1 reference

12 December 2020

The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis

1 reference

12 December 2020

Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals

1 reference

12 December 2020

Does frailty predict increased risk of falls and fractures? A prospective population-based study

1 reference

12 December 2020

Magnitude and economic effect of overuse of antisecretory therapy in the ambulatory care setting.

1 reference

12 December 2020

Long-term proton pump inhibitor therapy and falls and fractures in elderly women: a prospective cohort study

1 reference

12 December 2020

Overall benefit of antiretroviral treatment on the risk of fracture in HIV

1 reference

12 December 2020

Association between Helicobacter pylori Infection and Risk of Osteoporosis in Elderly Taiwanese Women with Upper Gastrointestinal Diseases: A Retrospective Patient Record Review

1 reference

12 December 2020

High economic burden of caring for patients with suspected extraesophageal reflux

1 reference

12 December 2020

Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies.

1 reference

12 December 2020

10.1007/S11938-014-0030-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

23 November 2017

1036022807

0 references

1 reference